NCT07441252

A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

Phase 2b Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Maridebart Cafraglutide in Adult Participants Living With Elevated Liver Fat and Obesity or Overweight

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 180 (estimated)
• Sponsor: Amgen · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

The main objective of this trial will be to determine whether maridebart cafraglutide is superior to placebo on reduction in liver fat content and body weight in participants living with obesity or overweight and elevated liver fat content, when administered in conjunction with reduced-calorie diet and increased physical activity.

Conditions

• Overweight or Obesity and Elevated Liver Fat

Interventions

Type	Name	Description
DRUG	Maridebart cafraglutide	Maridebart cafraglutide will be administered as a SC injection.
DRUG	Placebo	Placebo will be administered as a SC injection.

Timeline

• Start date: 2026-03-05
• Primary completion: 2027-09-29
• Completion: 2027-12-22
• First posted: 2026-02-27
• Last updated: 2026-04-16

Locations

14 sites across 1 country: United States

Regulatory

• FDA-regulated drug study